The AI Solution for Predicting Postoperative Complications Achieves Successful MDR Certification, Generating a New Product for Enhanced Patient Safety.

x-cardiac, a leading company in AI-based medical devices for the prediction of postoperative complications after cardiac surgery, has announced the successful certification of its new platform under the Medical Device Regulation (MDR). This groundbreaking certification marks a major milestone in medical technology and brings a new level of patient safety and treatment quality to critical situations.

The innovative x-cardiac-platform utilizes cutting-edge digital biomarkers to accurately predict postoperative complications, providing healthcare professionals with valuable insights to optimize patient care. With its MDR certification, the platform meets the highest safety and performance standards required in Europe.

The new product generation features two revolutionary plug-ins: x-c-bleeding and x-c-renal-injury. These plug-ins offer unprecedented support in detecting and treating bleeding and kidney damage after major heart surgery.

“We are thrilled to introduce our new product generation, which offers unprecedented possibilities for predicting postoperative complications in everyday clinical practice. We are excited to expand our reach beyond Germany, Austria, and Switzerland with the help of our sales partners,” says Oliver Höppner, CEO of x-cardiac. “The x-cardiac platform is a powerful medical device that has the potential to significantly improve patient care. We look forward to presenting it to the professional audience at the upcoming EACTS Annual Summit 2024 (European Association for Cardio-Thoracic Surgery) in Lisbon from October 10-12.”

Chief Medical Officer Prof. Dr. Alexander Meyer also expressed his enthusiasm for the new product generation, stating, “The x-cardiac-platform sets a new standard in clinical patient care by conducting local validation of algorithms for each customer. This ensures that our solutions are tailored to individual needs and circumstances, and optional fine tuning allows for even more precise results.”

For further information, please contact:

Oliver Höppner

x-cardiac GmbH

presse@xcardiac.com

www.xcardiac.com

Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.

Leave a Reply

Your email address will not be published. Required fields are marked *